Brokerages predict that Check Cap Ltd (NASDAQ:CHEK) will report earnings of ($0.36) per share for the current quarter, according to Zacks Investment Research. Zero analysts have made estimates for Check Cap’s earnings. The highest EPS estimate is ($0.33) and the lowest is ($0.39). Check Cap reported earnings of ($0.44) per share during the same quarter last year, which would indicate a positive year-over-year growth rate of 18.2%. The business is scheduled to issue its next earnings report on Monday, May 18th.

According to Zacks, analysts expect that Check Cap will report full-year earnings of ($1.10) per share for the current fiscal year, with EPS estimates ranging from ($1.71) to ($0.78). For the next year, analysts expect that the firm will post earnings of ($0.63) per share, with EPS estimates ranging from ($1.22) to ($0.26). Zacks’ earnings per share averages are a mean average based on a survey of sell-side analysts that follow Check Cap.

Check Cap (NASDAQ:CHEK) last announced its quarterly earnings data on Friday, March 6th. The medical research company reported ($0.46) earnings per share for the quarter, missing the Thomson Reuters’ consensus estimate of ($0.43) by ($0.03).

A number of equities research analysts have commented on the company. HC Wainwright reiterated a “buy” rating and issued a $2.00 price target (down previously from $13.00) on shares of Check Cap in a research report on Friday, April 24th. Zacks Investment Research raised Check Cap from a “hold” rating to a “buy” rating and set a $0.50 price objective on the stock in a research note on Friday.

Shares of CHEK stock opened at $0.53 on Thursday. The stock’s fifty day simple moving average is $0.77 and its 200 day simple moving average is $1.44. Check Cap has a twelve month low of $0.44 and a twelve month high of $2.80. The firm has a market capitalization of $5.77 million and a P/E ratio of -0.30.

About Check Cap

Check-Cap Ltd., a clinical stage medical diagnostics company, engages in the development of a capsule-based system that utilizes low-dose X-rays for screening of the colon to detect polyps, masses, and colorectal cancers in Israel. Its C-Scan system consists of C-Scan Cap, an X-ray scanning capsule, which is designed to measure, collect, and transmit structural information; C-Scan Track, a biocompatible unit worn on the patient's back for capsule control, tracking, and data recording; and C-Scan View, a personal computer-based software package, which is designed to retrieve and process clinical data from the C-Scan Track, and to reconstruct and produce 3D visualization of the colon's inner surface.

Recommended Story: How can investors benefit from after-hours trading?

Get a free copy of the Zacks research report on Check Cap (CHEK)

For more information about research offerings from Zacks Investment Research, visit

Receive News & Ratings for Check Cap Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Check Cap and related companies with's FREE daily email newsletter.